Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | BID | P55957 | 1/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.47 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423400 | 0.84 | MAPT (0.65) | ADRB1MAPTSMN1; SMN2LMNAALOX12 | |
| SCHEMBL1779655 | 0.82 | ADRB1 (0.70) | ADRB1MAPTSMN1; SMN2LMNAALOX12 | |
| SCHEMBL26418600 | 0.75 | ADRB1 (0.50) | ADRB1MAPTALOX12ALDH1A1MEN1 | |
| SCHEMBL24123984 | 0.75 | ALDH1A1 (0.46) | MAPTSMN1; SMN2LMNAALOX12L3MBTL1 | |
| SCHEMBL17543888 | 0.75 | ADRB1 (0.54) | ADRB1MAPTSMN1; SMN2LMNAALOX12 | |
| SCHEMBL23126674 | 0.74 | GAA (0.55) | ADRB1MAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL9830834 | 0.74 | ADRB1 (0.68) | ADRB1MAPTSMN1; SMN2LMNAALOX12 | |
| SCHEMBL12006357 | 0.74 | MAPT (0.69) | MAPTSMN1; SMN2LMNAALOX12L3MBTL1 | |
| SCHEMBL14996510 | 0.74 | TP53 (0.54) | MAPTSMN1; SMN2LMNAHTR1AALDH1A1 | |
| SCHEMBL4169525 | 0.73 | LGMN (0.54) | ADRB1MAPTSMN1; SMN2LMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943630-B2 | 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-05-17 | — | — | US | claimed |
| EP-1917264-B1 | NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-11-17 | — | — | EP | claimed |
| US-20090111841-A1 | Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | ANIONA APS (DK) | 2009-04-30 | — | — | US | claimed |
| EP-1917264-A1 | NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-05-07 | — | — | EP | claimed |
| WO-2007000463-A1 | NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-01-04 | — | — | WO | claimed |
| US-7943630-B2 | 3,9-diaza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-05-17 | — | — | US | disclosed |
| EP-1917264-B1 | NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-11-17 | — | — | EP | disclosed |
| US-20090111841-A1 | Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | ANIONA APS (DK) | 2009-04-30 | — | — | US | disclosed |
| EP-1917264-A1 | NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007000463-A1 | NOVEL 3,9-DIAZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111841-A1 | Novel 3,9-Diaza-Spiro[5,5]Undecane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | ADRB1 38/4885MAPT 1180/4885SMN1; SMN2 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.